Raymond James analyst Brian Peterson maintains Avalara (NYSE:AVLR) with a Outperform and lowers the price target from $155 to $100.
Silverback Therapeutics Announced FDA’s Acceptance of ARS Pharmaceuticals’ NDA for Neffy (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) Including Anaphylaxis
Silverback Therapeutics, Inc. (Nasdaq: SBTX) ("Silverback") today announced that the U.S.
